All In Biotech

Drug Trial Radar · NCT03446781

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)

Last checked: Nov 19, 2026Latest source record: Oct 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 422 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

422

Actual

Start

Feb 8, 2018

Primary completion

Sep 26, 2018

Study completion Sep 26, 2018

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the subject using the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) and by the Investigator using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) will be eligible. The eligibility of the buttocks will be confirmed on Day 1. Once the eligibility of the buttocks is confirmed, subjects will be randomly assigned to a treatment group (EN3835 0.84 mg per buttock or placebo) in a 1:1 ratio within an investigational site. Each subject will receive a treatment course which consists of up to 3 treatment visits (sessions), separated by 21 days (ie, Days 1, 22, and 43). Each treatment visit will consist of 12 injections (0.3 mL per injection of EN3835 0.07 mg/injection or placebo; 0.84 mg in 3.6 mL per buttock) in each of the two buttocks for a total volume of 7.2 mL (1.68 mg). Selection of dimples to be treated in the buttocks will be at the discretion of the Investigator. End of study will occur at study day 71.

Conditions

  • Edematous Fibrosclerotic Panniculopathy (Cellulite)

Interventions

  • EN3835Biological

    Collagenase clostridium histolyticum

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 2-level Composite Responders for the Target ButtockTime frame: Day 71

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Endo Clinical Trial Site #1

    Glendale, Arizona

  • Endo Clinical Trial Site #2

    North Little Rock, Arkansas

  • Endo Clinical Trial Site #3

    Beverly Hills, California

  • Endo Clinical Trial Site #4

    Murrieta, California

  • Endo Clinical Trial Site #5

    Newport Beach, California

  • Endo Clinical Trial Site #6

    San Diego, California

  • Endo Clinical Trial Site #7

    Greenwood Village, Colorado

  • Endo Clinical Trial Site #8

    Coral Gables, Florida

  • Endo Clinical Trial Site #9

    Miami, Florida

  • Endo Clinical Trial Site #10

    Nampa, Idaho

  • Endo Clinical Trial Site #11

    Carmel, Indiana

  • Endo Clinical Trial Site #12

    Metairie, Louisiana

  • Endo Clinical Trial Site #13

    New Orleans, Louisiana

  • Endo Clinical Trial Site #14

    Warren, Michigan

  • Endo Clinical Trial Site #15

    Montclair, New Jersey

  • Endo Clinical Trial Site #16

    East Setauket, New York

  • Endo Clinical Trial Site #17

    New York, New York

  • Endo Clinical Trial Site #18

    Cincinnati, Ohio

  • Endo Clinical Trial Site #19

    Nashville, Tennessee

  • Endo Clinical Trial Site #20

    Austin, Texas

  • Endo Clinical Trial Site #21

    Beaumont, Texas

  • Endo Clinical Trial Site #22

    Houston, Texas

  • Endo Clinical Trial Site #23

    San Antonio, Texas

  • Endo Clinical Trial Site #24

    Salt Lake City, Utah

  • Endo Clinical Trial Site #25

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.